APG-808 is under clinical development by Apogee Therapeutics and currently in Phase I for Unspecified Immunological Disorders.

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.

The spread of HMPV in China has caused scare among people worldwide. Social media shows pictures of overwhelming number of patients in China. As the virus is being compared with the Covid-19, let us ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

HMPV cases are rising in China, with 327 reported in 2024, a 45% increase from 225 cases in 2023. The virus, causing symptoms ...

First identified in 2001, HMPV belongs to the Pneumoviridae family, closely related to the Respiratory Syncytial Virus (RSV).

Just when you thought 2025 was finally going to let you breathe (literally and figuratively), here comes another respiratory ...

The odds are high you’ve had a cough before in your life, but each time can throw you for a loop. Even though you’ve been ...